Testing heart blood tests and scans to monitor Fabry disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study checks whether certain heart-related blood tests and heart scans can help monitor people with Fabry disease. It may be useful for both people who have never received enzyme replacement therapy and those who have.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have a confirmed diagnosis of Fabry disease.
- You have at least one abnormal heart finding, such as an abnormal heart blood marker, higher plasma Gb3 or Lyso-Gb3, an abnormal ECG, or an abnormal heart-related image.
- You are either not yet treated with enzyme replacement therapy (ERT) or you have been treated with agalsidase beta (ERT).
- You can agree to attend required clinic visits and complete study procedures.
- You are willing to sign the informed consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether agalsidase alfa can reduce heart inflammation in people with Fabry disease who have heart problems. You may qualify if you have not had this treatment in the past year.
This study tests an enzyme replacement therapy (agalsidase alfa) for Fabry disease in Chinese children and adults. It's an observational study that follows patients who receive the treatment as part of their regular care.
This trial is testing a new enzyme replacement therapy called Fabagal for people with Fabry disease who have not had prior treatment. It aims to see if it helps with kidney, heart, or brain problems caused by the disease.
This trial tests if enzyme replacement therapy works well and is safe for Fabry disease. It is for people who are already prescribed this treatment.
This study is for people with Fabry disease who are taking or planning to take the medication Elfabrio (pegunigalsidase alfa). It will look at how safe and effective the treatment is in real-world use.
This trial tests a new medicine called EXG110, given through a vein, for people with Fabry disease. It aims to see if the medicine is safe and helps with symptoms related to the heart or kidneys.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.